arrow_back Trending Legislation
Share share

Increased Funding and Focus on Sickle Cell Disease Treatment and Research until 2028.

This bill reauthorizes the sickle cell disease prevention and treatment demonstration program with increased funding. It expands the scope to include the treatment and prevention of complications associated with the disease. Additionally, it allows for grants, contracts, or cooperative agreements to be awarded to entities carrying out these tasks.
Key points
Annual funding is increased from $4.455 million to $8.205 million for fiscal years 2024 through 2028.
The scope of programs is expanded to include the prevention and treatment of complications of sickle cell disease.
Funding mechanisms are updated to include grants, contracts, or cooperative agreements.
It is the sense of Congress that further research should be undertaken to find cures for heritable blood disorders.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023
Print number: S 1852
Sponsor: Sen. Scott, Tim [R-SC]
Process start date: 2023-06-07
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increased Funding and Focus on Sickle Cell Disease Treatment and Research until 2028.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1852.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-06-07.

What are the main provisions?

Key points include:

  • Annual funding is increased from $4.455 million to $8.205 million for fiscal years 2024 through 2028.
  • The scope of programs is expanded to include the prevention and treatment of complications of sickle cell disease.
  • Funding mechanisms are updated to include grants, contracts, or cooperative agreements.
  • It is the sense of Congress that further research should be undertaken to find cures for heritable blood disorders.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Scott, Tim [R-SC].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 201.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

Analysis and Potential Impact of S 1852

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health